This year so far, some of the biggest pharmaceutical corporations in the world have withdrawn about £2bn in proposed investment from the UK. One has even threatened to withhold new medicines from NHS patients. Taken together, it’s hard not to conclude that big pharma is at war with the UK.
Merck has scrapped a £1bn research facility, while AstraZeneca ditched a £450m vaccine lab and is rethinking an expansion of another research unit. Bristol Myers Squibb (BMS) has cancelled 34 partnerships with the NHS in the last year, and Eli Lilly, Sanofi and Novartis are all believed to have put investments “on hold”. BMS is also threatening to play hardball with its new schizophrenia drug, saying it is “prepared to make the difficult decision” to “walk away” if the NHS won’t pay the price the corporation wants to charge.
